Nasus Pharma Ltd. announced a change in chief executive officer, with Dan Teleman resigning effective July 22, 2026, and Brendan P. O’Grady appointed as CEO effective July 27, 2026. O’Grady brings extensive pharmaceutical leadership experience, including previous CEO roles at Assertio Holdings and senior positions at Teva Pharmaceuticals and Glenmark Pharmaceuticals. The transition positions the company to advance its lead candidate NS002 toward a pivotal trial in the fourth quarter of 2026, with topline data expected in the first quarter of 2027. Nasus Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative intranasal therapies using its proprietary Nasax technology platform.
